Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

7(77.8%)

N/A

1(11.1%)

Early Phase 1

1(11.1%)

9Total

Phase 1(7)

N/A(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07139431Phase 1Not Yet Recruiting

A Study of [89Zr]-Oxine-NCR100 Injection for the Cellular Distribution

Role: lead

NCT06978920Phase 1Recruiting

A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease

Role: lead

NCT06941350Phase 1Not Yet Recruiting

A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD

Role: lead

NCT06825169Phase 1Not Yet Recruiting

A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects With Interstitial Lung Disease

Role: lead

NCT06741098Phase 1Not Yet Recruiting

A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis（ KOA）

Role: lead

NCT06441084Phase 1Not Yet Recruiting

A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation

Role: lead

NCT06245018Not ApplicableNot Yet Recruiting

A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor

Role: lead

NCT06049342Phase 1Unknown

A Trial to Evaluate the Safety, Tolerability, and Efficacy of NCR100 Injection in the Treatment of Subjects With KOA

Role: lead

NCT05371730Early Phase 1Not Yet Recruiting

A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes

Role: lead

All 9 trials loaded